Case File
efta-efta00956909DOJ Data Set 9OtherFrom: "McGraw, Thomas"
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00956909
Pages
1
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: "McGraw, Thomas"
To: Jeffrey Epstein <[email protected]>
Subject: RE:
Date: Tue, 19 Mar 2013 16:17:32 +0000
Assuming first that the partnership, the option contract & capital account positions/values are respected, then I think an
option written that deeply in the money (in return for the economic interest of preferred cash flow on the units) would
raise issues not only as to sale of the art for income tax purposes depending on capital account provisions & subsequent
distributions out of the partnership but also as to a sale for NY sales tax purposes which as I'm sure you are aware is a
rather liberal definition in NY including precedents on various conditional sales transactions
IRS Circular 230 Disclosure:
JPMorgan Chase & Co. and its aff iliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters
contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection
with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Chase & Co. of any of the
matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.
From: Jeffrey Epstein [maittoleevacation@gmaILoom]
Sent: Monday, March 18, 2013 2:46 PM
To: McGraw, Thomas
Subject:
if i could seperate title from value, it seems to me easy to exchange the value in my art for the partnership
interest. Ilc with two classes one holds title. ( vote ) ,the other full value,
if i contributed an option at 50
million for the value, currently at 2 billion , I might have a disguised sale purpose for federal , grantor trust no
issue, but i can't imaginge a disguised sales tax ?
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation®gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
This email is confidential and subject to important disclaimers and conditions including on offers for the
purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege,
and legal entity disclaimers, available at http://wwwjpmorgan.com/pages/disclosures/email.
EFTA00956909
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]URL
http://wwwjpmorgan.com/pages/disclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.